Virpax Pharmaceuticals 8-K Filing: Key Insights from January 15, 2025 Report

Based on the provided XML section of the financial report, here are the key extracted insights:

Entity Information:

Company Name: Virpax Pharmaceuticals, Inc.
CIK (Central Index Key): 0001708331
IRS Employer Identification Number: 82-1510982
Address: 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312
Contact Number: (610) 727-4597

SEC Filing Details:

Filing Type: 8-K (a report of unscheduled material events or corporate changes)
Filing Date: January 15, 2025
SEC File Number: 001-40064

Stock Information:

Common Stock Par Value: $0.00001 per share
Ticker Symbol: VRPX
Market: NASDAQ

Reporting Context:

Reporting Date: The report covers the date of January 15, 2025, indicating a specific event or update as of that date.

Units of Measure:

Financial measures are reported in USD (U.S. Dollars) and shares.

Insights:

The filing indicates that Virpax Pharmaceuticals, Inc. has made a significant announcement or corporate change reported in the 8-K on January 15, 2025.
The company remains publicly traded under the ticker VRPX on NASDAQ, with a very low par value of its common stock, which may indicate a focus on growth and potential capital raising strategies.
The provided contact information may be useful for investors or analysts seeking additional details regarding the company's operations or the implications of the 8-K filing.

Overall, this report allows for a basic understanding of the company's current standing and regulatory compliance as of the specified date. Further insights would require analyzing the contents of the actual 8-K filing.